indicate that one cycle of treatment is sufficient to expand and generate de novo clones (figure 2). We developed a primary cell cytotoxicity assay and observe that cytotoxic potency is target dependent. Target cell killing and T cell activation/proliferation depend on CD33 clustering, and both CD4 and CD8 T cells can engage and kill target cells. This is illustrated in assays with KG-1 (M2, clustered) and KG-1a (M0, not clustered) cell lines, in which the KG-1 cells have an EC50 15–20 fold lower than the M0 cell line (figure 3). In addition, there is little to no detectable binding or killing of monocytes or neutrophils, which is consistent with the absence of neutropenia in patients enrolled in the trial to date.

Abstract 692 Figure 2 TcRb CDR3 sequencing of an ovarian cancer patient shows extensive clonal expansion upon treatment. Scatter plots represent clonal abundance in the periphery between Baseline (C1D1) and C1D12 using the differential Abundance tool (Adaptive Biotechnology)

Abstract 692 Figure 3 Cytotoxicity assay using fresh primary T cells demonstrates target selectivity on two cell lines with equivalent CD33 surface expression. T cell activation by AMV564 at clinically relevant doses is equivalent to CD3/CD28 stimulation

Conclusions AMV564 is a potent conditional T cell agonist which is clinically active. We demonstrate that the combination of T cell activation, increased T cell diversity, and target specificity allow AMV564 to deplete MDSCs and restore a native immune response to cancer.

Ethics Approval This study was approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) at each participating institution.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0692

693 APX601, A NOVEL TNFR2 ANTAGONIST ANTIBODY FOR CANCER IMMUNOTHERAPY

Erin Fillibert*, Sushma Krishnan, Ryan Alvarado, George Huang, Francis Bahjat, Xiaodong Yang. Apexigen, Inc., San Carlos, CA, USA

Background A key barrier to effective immunotherapy for cancer is the immunosuppressive tumor microenvironment (TME) characterized by infiltrating regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC). While depletion of immune-suppressive cells is a promising cancer immunotherapy strategy, current approaches are ineffective due to lack of specificity and safety concerns. Tumor Necrosis Factor Receptor 2 (TNFR2) is emerging as a novel, selective target to overcome immunosuppression in TME. TNFR2 expression is generally restricted to highly immunosuppressive cell populations in the TME and the TNFR2-TNF-α pathway plays an important role in the generation and survival of these cells. TNFR2 is also an oncogene upregulated on certain tumors and can enhance tumor cell survival. Thus, targeting TNFR2 is a promising therapeutic approach with multiple potential mechanisms of action.

Methods A diverse panel of antibodies to TNFR2 was created using APXiMAB™, Apexigen’s proprietary rabbit monoclonal antibody technology. A robust assessment of over 100 antibody candidates for TNFR2 binding, TNF-α blockade and functional assays yielded APX601, a humanized IgG1 antibody, as the lead therapeutic candidate. The ability of APX601 to reverse immune suppression was assessed in Treg and MDSC suppression assays. In addition, the ability of APX601 to deplete TNFR2-expressing Treg and tumor cells was assessed both in vitro and in vivo using the mouse Colo205 xenograft model.

Results APX601 binds specifically to human TNFR2 with high affinity (Kd = 47 pM) and recognizes a unique epitope in the CRD1 domain of TNFR2. APX601 is a potent antagonist that blocks the TNFR2-TNF-α interaction in cell-based ligand binding assays (IC50 = 0.149 nM). APX601 is capable of reversing immune suppression via two mechanisms: 1) significant blockade of the immunosuppressive functions of both Tregs and MDSCs by inhibiting the binding of TNFR2 to its ligand TNF-α and 2) depletion of TNFR2-expressing Tregs, MDSC and tumor cells via antibody-dependent cell cytotoxicity (ADCC) (EC50 = 1.14 nM) and ADCP (EC50 = 0.71 nM) effector functions.

Conclusions APX601 is a potent TNFR2 antagonist antibody that reverses immune suppression by targeting TNFR2-expressing Treg and MDSC, and induces killing of tumor cells. Our data support the further development of APX601, a promising immunotherapeutic antibody with multiple potential mechanisms of action, for the treatment of a variety of solid tumors.

Ethics Approval Healthy human blood samples were obtained from Stanford Blood Center (Palo Alto, CA) from consenting donors under an approved protocol.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0693

694 NC410 IS A NOVEL IMMUNOMEDICINE FOR THE TREATMENT OF SOLID TUMORS

Linjie Tian, 2M Ines Pascual Ramos, 2Emma de Ruiter, 2Ana Paucarmayta, 2Eline Elshof, 2Stefan Willems, 1Chang Song, 2Zachary Cusumano, 2Jason Bosiacki, 2Linda Liu, 1Solomon Langermann, 1Linde Meyard, 2Dallas Files*. NextCure, Inc., Beltsville, MD, USA; 2University Medical Center, Utrecht, Utrecht, Netherlands

Background Abnormalities in the extracellular matrix of tumor microenvironments support tumor progression, lead to...
immune dysfunction, and provide a target for cancer therapeutics. Collagens are a primary component of the extracellular matrix. Abnormal levels of collagen and of the collagen-domain containing complement component 1q (C1q) in tumor microenvironments has been proposed to disrupt anti-tumor immunity. LAIR-1 is an adhesion molecule and inhibitory receptor expressed on the cell surface of several immune cell subsets. LAIR-1 binding to collagen-like domains present in collagens and C1q inhibit immune cell function. LAIR-2 is a soluble homolog of LAIR-1 that binds to and outcompetes LAIR-1 binding to collagens and C1q and serves as a natural decoy to promote immune function.

**Methods**

Taking advantage of a natural decoy system, we designed a protein biologic, NC410, composed of LAIR-2 fused with a functional IgG1 Fc domain to target collagen-rich tumors and promote immune activation, infiltration and effector function.

**Results**

NC410 has increased avidity due to Fc mediated dimerization, and blocks LAIR-1 interactions with ligands, and LAIR-1 signaling. In vivo administration of NC410 in humanized tumor models reduced tumor growth in a dose dependent fashion. NC410 increased the numbers of infiltrating human CD8+ and CD4+ T cells in the tumor, which is associated with increased levels of chemokines in the local tumor environment. Effector function was also enhanced, as denoted by increased levels of IFN-gamma and Granzyme B in the local tumor environment. In addition, NC410 increased specific collagen degradative products in the serum of humanized tumor-bearing mice, suggesting NC410 may promote tumor microenvironment remodeling and immune accessibility to further promote anti-tumor immunity.

**Conclusions**

These data support NC410 as a novel therapeutic for targeting collagen-rich tumors and enabling normalization of the tumor-immune microenvironment. FIH studies have recently been initiated with NC410.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0694

**BRENTUXIMAB VEDOTIN, A CD30-DIRECTED ANTIBODY-DRUG CONJUGATE, SELECTIVELY DEPLETES ACTIVATED TREGS IN VITRO AND IN VIVO**

Bryan Grogan*, Reice James, Michelle Ulrich, Shyra Gardai, Ryan Heiser, Reice James. Seattle Genetics, Inc., Bothell, WA, USA

**Background**

Regulatory T cells (Tregs) play an important role in maintaining immune homeostasis, preventing excessive inflammation in normal tissues. In cancer, Tregs hamper anti-tumor immunosurveillance and facilitate immune evasion. Selective targeting of intratumoral Tregs is a potentially promising treatment approach. Orthogonal evaluation of tumor-infiltrating lymphocytes (TILs) in solid tumors in mice and humans have identified CCR8, and several tumor necrosis family receptors (TNFRs), including TNFSFR8 (CD30), as receptors differentially upregulated on intratumoral Tregs compared to normal tissue Tregs and other intratumoral T cells, making these intriguing therapeutic targets.Brentuximab vedotin (BV) is approved for classical Hodgkin lymphoma (cHL) across multiple lines of therapy including frontline use in stage III/IV cHL in combination with doxorubicin, vinblastine, and dacarbazine. BV is also approved for certain CD30-expressing T-cell lymphomas. BV is comprised of a CD30-directed monoclonal antibody conjugated to the highly potent microtubule-disrupting agent monomethyl auristatin E (MMAE). The activity of BV in lymphomas is thought to primarily result from tumor directed intracellular MMAE release, leading to mitotic arrest and apoptotic cell death. The role CD30 plays in normal